A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-related hepatitis

Khaled Sayed; Christine E. Dolin; Daniel W. Wilkey; Jiang Li; Toshifumi Sato; Juliane I Beier; Josepmaria Argemi; Ramon Bataller; Abdus S Wahed; Michael L Merchant; Panayiotis V Benos; Gavin E Arteel

doi:10.1101/2023.12.13.23299905

ABSTRACT

Alcohol-related hepatitis (AH) is plagued with high mortality and difficulty in identifying at-risk patients. The extracellular matrix undergoes significant remodeling during inflammatory liver injury that can be detected in biological fluids and potentially used for mortality prediction. EDTA plasma samples were collected from AH patients (n= 62); Model for End-Stage Liver Disease (MELD) score defined AH severity as moderate (12-20; n=28) and severe (>20; n=34). The peptidome data was collected by high resolution, high mass accuracy UPLC-MS. Univariate and multivariate analyses identified differentially abundant peptides, which were used for Gene Ontology, parent protein matrisomal composition and protease involvement. Machine learning methods were used on patient-specific peptidome and clinical data to develop mortality predictors. Analysis of plasma peptides from AH patients and healthy controls identified over 1,600 significant peptide features corresponding to 130 proteins. These were enriched for ECM fragments in AH samples, likely related to turnover of hepatic-derived proteins. Analysis of moderate versus severe AH peptidomes showed a shift in abundance of peptides from collagen 1A1 and fibrinogen A proteins. The dominant proteases for the AH peptidome spectrum appear to be CAPN1 and MMP12. Increase in hepatic expression of these proteases was orthogonally-validated in RNA-seq data of livers from AH patients. Causal graphical modeling identified four peptides directly linked to 90-day mortality in >90% of the learned graphs. These peptides improved the accuracy of mortality prediction over MELD score and were used to create a clinically applicable mortality prediction assay. A signature based on plasma peptidome is a novel, non-invasive method for prognosis stratification in AH patients. Our results could also lead to new mechanistic and/or surrogate biomarkers to identify new AH mechanisms.

Lay summary We used degraded proteins found the blood of alcohol-related hepatitis patients to identify new potential mechanisms of injury and to predict 90 day mortality.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Access to healthy control and AH consortium samples provided by Craig McClain, MD and Vatsalya Vatsalya, MD through the University of Louisville Alcohol Research Center (P50 AA024337). Supported, in part, by grants from NIH (R01 DK130294, R01 AA021978, R01 HL157879, R01 HL127349, P20 GM113226, P30 DK120531)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of Louisville Human Studies Committee Human approved sample collection and use of de-identified samples provided in this study. All study subjects provided informed consent prior to sample collection. All studies were conducted in compliance with the Declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data availability statement

Proteomic files were deposited in MassIVE (http://massive.ucsd.edu/) as study (MassIVE MSV000093513) entitled “Alcoholic hepatitis plasma degradome”. Data include (A) the primary data files (.RAW), (B) peak list files (.mzML), (C) sample key, (D) the sequence databases (human UniprotKB reviewed reference proteomes), and (E) excel files containing Peaksdb results for de novo peptide sequence assignment. The shared data will be released from private embargo for public access upon the manuscript’s acceptance for publication. All other data will be made available on request.